Header Logo

Connection

Michael Cookson to Prostatic Neoplasms

Back to Details
This is a "connection" page, showing publications Michael Cookson has written about Prostatic Neoplasms.
Michael Cookson
Connection Strength
12.618
Prostatic Neoplasms
  1. Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART I. J Urol. 2021 Jan; 205(1):14-21.
    View in: PubMed
    Score: 0.562
  2. The changing landscape in the management of newly diagnosed castration sensitive metastatic prostate cancer. Investig Clin Urol. 2020 02; 61(Suppl 1):S3-S7.
    View in: PubMed
    Score: 0.536
  3. Urology perspective on the expanding world of germline testing for prostate cancer. Can J Urol. 2019 10; 26(5 Suppl 2):5-6.
    View in: PubMed
    Score: 0.525
  4. Recent trends in the management of advanced prostate cancer. F1000Res. 2018; 7.
    View in: PubMed
    Score: 0.489
  5. Editorial Comment for Bolton et al. J Endourol. 2015 Jul; 29(7):850.
    View in: PubMed
    Score: 0.391
  6. Best evidence regarding the superiority or inferiority of robot-assisted radical prostatectomy. Urol Clin North Am. 2014 Nov; 41(4):493-502.
    View in: PubMed
    Score: 0.368
  7. Prostate cancer: Could sensitive PSA assays expedite salvage radiotherapy? Nat Rev Urol. 2014 Jan; 11(1):14-5.
    View in: PubMed
    Score: 0.351
  8. Castration-resistant prostate cancer: AUA Guideline. J Urol. 2013 Aug; 190(2):429-38.
    View in: PubMed
    Score: 0.337
  9. Positive surgical margins at radical prostatectomy: much ado about nothing? Urol Oncol. 2013 Apr; 31(3):285-7.
    View in: PubMed
    Score: 0.335
  10. A 57-year-old man with a history of prostatectomy and pelvic irradiation presents with recurrent urinary tract infections, hematuria, and pelvic pain. Urology. 2013 Feb; 81(2):221-5.
    View in: PubMed
    Score: 0.331
  11. Complications of pelvic lymph node dissection for prostate cancer. Curr Urol Rep. 2011 Jun; 12(3):203-8.
    View in: PubMed
    Score: 0.295
  12. Margin control in open radical prostatectomy: what are the real outcomes? Urol Oncol. 2010 Mar-Apr; 28(2):205-9.
    View in: PubMed
    Score: 0.270
  13. Should pelvic lymph node dissection be performed with radical prostatectomy? No. J Urol. 2010 Apr; 183(4):1284-5.
    View in: PubMed
    Score: 0.270
  14. Comparison of transfusion requirements between open and robotic-assisted laparoscopic radical prostatectomy. BJU Int. 2010 Oct; 106(7):1036-40.
    View in: PubMed
    Score: 0.269
  15. Impact of surgeon and hospital volume on outcomes of radical prostatectomy. Urol Oncol. 2010 May-Jun; 28(3):243-50.
    View in: PubMed
    Score: 0.255
  16. Outcomes of patients undergoing radical cystoprostatectomy for bladder cancer with prostatic involvement on final pathology. BJU Int. 2009 Oct; 104(8):1091-7.
    View in: PubMed
    Score: 0.254
  17. A critical review of clinical practice guidelines for the management of clinically localized prostate cancer. J Urol. 2008 Aug; 180(2):451-9; discussion 460.
    View in: PubMed
    Score: 0.240
  18. Effect of a large prostate gland on open and robotically assisted laparoscopic radical prostatectomy. BJU Int. 2008 May; 101(9):1140-4.
    View in: PubMed
    Score: 0.238
  19. A comparison of the incidence and location of positive surgical margins in robotic assisted laparoscopic radical prostatectomy and open retropubic radical prostatectomy. J Urol. 2007 Dec; 178(6):2385-9; discussion 2389-90.
    View in: PubMed
    Score: 0.230
  20. The evidence-based pathway for peri-operative management of open and robotically assisted laparoscopic radical prostatectomy. BJU Int. 2007 May; 99(5):1103-8.
    View in: PubMed
    Score: 0.219
  21. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol. 2007 Feb; 177(2):540-5.
    View in: PubMed
    Score: 0.218
  22. Impact of positive surgical margins after radical prostatectomy. Urology. 2006 Aug; 68(2):249-52.
    View in: PubMed
    Score: 0.211
  23. Tumour volume is an independent predictor of prostate-specific antigen recurrence in patients undergoing radical prostatectomy for clinically localized prostate cancer. BJU Int. 2006 Jun; 97(6):1169-72.
    View in: PubMed
    Score: 0.208
  24. Mechanisms leading to the development of hormone-resistant prostate cancer. Urol Clin North Am. 2006 May; 33(2):201-10, vii.
    View in: PubMed
    Score: 0.207
  25. Positive influence of robotically assisted laparoscopic prostatectomy on the collaborative-care pathway for open radical prostatectomy. BJU Int. 2006 Mar; 97(3):473-5.
    View in: PubMed
    Score: 0.205
  26. Safely reducing length of stay after open radical retropubic prostatectomy under the guidance of a clinical care pathway. Cancer. 2005 Aug 15; 104(4):747-51.
    View in: PubMed
    Score: 0.197
  27. A pilot randomized clinical trial of a smartphone-based application to support at-home PSA screening and culturally tailored prostate cancer education for African American men: A study protocol. Contemp Clin Trials. 2024 Dec; 147:107737.
    View in: PubMed
    Score: 0.187
  28. The free/total prostate-specific antigen ratio (%fPSA) is the best predictor of tumor involvement in the radical prostatectomy specimen among men with an elevated PSA. Urol Oncol. 2002 Sep-Oct; 7(5):195-8.
    View in: PubMed
    Score: 0.161
  29. Percent of cancer in the biopsy set predicts pathological findings after prostatectomy. J Urol. 2002 May; 167(5):2032-5; discussion 2036.
    View in: PubMed
    Score: 0.157
  30. Health related quality of life assessment after radical prostatectomy in men with prostate specific antigen only recurrence. J Urol. 2001 Dec; 166(6):2286-90.
    View in: PubMed
    Score: 0.153
  31. Prediction of tumour volume and pathological stage in radical prostatectomy specimens is not improved by taking more prostate needle-biopsy cores. BJU Int. 2001 Nov; 88(7):722-6.
    View in: PubMed
    Score: 0.152
  32. Ratio of free-to-total prostate specific antigen correlates with tumor volume in patients with increased prostate specific antigen. J Urol. 2001 Feb; 165(2):455-8.
    View in: PubMed
    Score: 0.144
  33. Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. J Clin Oncol. 2020 08 20; 38(24):2798-2811.
    View in: PubMed
    Score: 0.138
  34. Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer. N Engl J Med. 2020 06 04; 382(23):2187-2196.
    View in: PubMed
    Score: 0.137
  35. 8q24 genetic variation and comprehensive haplotypes altering familial risk of prostate cancer. Nat Commun. 2020 03 23; 11(1):1523.
    View in: PubMed
    Score: 0.136
  36. Optimizing the role of androgen deprivation therapy in advanced prostate cancer: Challenges beyond the guidelines. Prostate. 2020 05; 80(6):527-544.
    View in: PubMed
    Score: 0.135
  37. Update on transrectal ultrasound-guided needle biopsy of the prostate. Mol Urol. 2000; 4(3):93-7; discussion 99.
    View in: PubMed
    Score: 0.134
  38. Transition from androgenic to neurosteroidal action of 5a-androstane-3a, 17ß-diol through the type A ?-aminobutyric acid receptor in prostate cancer progression. J Steroid Biochem Mol Biol. 2018 04; 178:89-98.
    View in: PubMed
    Score: 0.115
  39. Prognostic significance of prostate-specific antigen in stage T1c prostate cancer treated by radical prostatectomy. Urology. 1997 Jun; 49(6):887-93.
    View in: PubMed
    Score: 0.112
  40. Pathological staging and biochemical recurrence after neoadjuvant androgen deprivation therapy in combination with radical prostatectomy in clinically localized prostate cancer: results of a phase II study. Br J Urol. 1997 Mar; 79(3):432-8.
    View in: PubMed
    Score: 0.110
  41. Correlation between Gleason score of needle biopsy and radical prostatectomy specimen: accuracy and clinical implications. J Urol. 1997 Feb; 157(2):559-62.
    View in: PubMed
    Score: 0.109
  42. Glutathione S-transferase PI (GST-pi) class expression by immunohistochemistry in benign and malignant prostate tissue. J Urol. 1997 Feb; 157(2):673-6.
    View in: PubMed
    Score: 0.109
  43. The lack of predictive value of prostate specific antigen density in the detection of prostate cancer in patients with normal rectal examinations and intermediate prostate specific antigen levels. J Urol. 1995 Sep; 154(3):1070-3.
    View in: PubMed
    Score: 0.099
  44. Biochemical recurrence-free survival after robotic-assisted laparoscopic vs open radical prostatectomy for intermediate- and high-risk prostate cancer. Urology. 2014 Jun; 83(6):1309-15.
    View in: PubMed
    Score: 0.090
  45. An expressed retrogene of the master embryonic stem cell gene POU5F1 is associated with prostate cancer susceptibility. Am J Hum Genet. 2014 Mar 06; 94(3):395-404.
    View in: PubMed
    Score: 0.089
  46. Hormonal therapy for metastatic prostate cancer: issues of timing and total androgen ablation. South Med J. 1994 Jan; 87(1):1-6.
    View in: PubMed
    Score: 0.088
  47. Optimization of initial prostate biopsy in clinical practice: sampling, labeling and specimen processing. J Urol. 2013 Jun; 189(6):2039-46.
    View in: PubMed
    Score: 0.083
  48. Salvage robotic assisted laparoscopic radical prostatectomy: a single institution, 5-year experience. J Urol. 2013 Feb; 189(2):507-13.
    View in: PubMed
    Score: 0.081
  49. Racial variation in the quality of surgical care for prostate cancer. J Urol. 2012 Oct; 188(4):1279-85.
    View in: PubMed
    Score: 0.080
  50. Spurious elevation of serum PSA after curative treatment for prostate cancer: clinical consequences and the role of heterophilic antibodies. Prostate Cancer Prostatic Dis. 2012 Jun; 15(2):182-8.
    View in: PubMed
    Score: 0.076
  51. Prostate size as a predictor of Gleason score upgrading in patients with low risk prostate cancer. J Urol. 2011 Dec; 186(6):2221-7.
    View in: PubMed
    Score: 0.076
  52. Long-term efficacy and tolerability of once-yearly histrelin acetate subcutaneous implant in patients with advanced prostate cancer. BJU Int. 2012 Jan; 109(2):226-32.
    View in: PubMed
    Score: 0.075
  53. Oxidative stress measured by urine F2-isoprostane level is associated with prostate cancer. J Urol. 2011 Jun; 185(6):2102-7.
    View in: PubMed
    Score: 0.073
  54. The associations between statin use and prostate cancer screening, prostate size, high-grade prostatic intraepithelial neoplasia (PIN), and prostate cancer. Cancer Causes Control. 2011 Mar; 22(3):417-26.
    View in: PubMed
    Score: 0.071
  55. Tumor volume as a predictor of adverse pathologic features and biochemical recurrence (BCR) in radical prostatectomy specimens: a tale of two methods. World J Urol. 2011 Feb; 29(1):15-20.
    View in: PubMed
    Score: 0.071
  56. Smaller prostate size predicts high grade prostate cancer at final pathology. J Urol. 2010 Sep; 184(3):930-7.
    View in: PubMed
    Score: 0.070
  57. Comparative analysis of whole mount processing and systematic sampling of radical prostatectomy specimens: pathological outcomes and risk of biochemical recurrence. J Urol. 2010 Oct; 184(4):1334-40.
    View in: PubMed
    Score: 0.070
  58. NCCN clinical practice guidelines in oncology: prostate cancer early detection. J Natl Compr Canc Netw. 2010 Feb; 8(2):240-62.
    View in: PubMed
    Score: 0.067
  59. Robotic assisted laparoscopic prostatectomy versus radical retropubic prostatectomy for clinically localized prostate cancer: comparison of short-term biochemical recurrence-free survival. J Urol. 2010 Mar; 183(3):990-6.
    View in: PubMed
    Score: 0.067
  60. Impact of positive apical surgical margins on likelihood of biochemical recurrence after radical prostatectomy. J Urol. 2009 Dec; 182(6):2695-701.
    View in: PubMed
    Score: 0.066
  61. Pathological stage T2 subgroups to predict biochemical recurrence after prostatectomy. J Urol. 2009 Nov; 182(5):2291-5.
    View in: PubMed
    Score: 0.065
  62. Risk factors for urothelial carcinoma of the prostate in patients undergoing radical cystoprostatectomy for bladder cancer. BJU Int. 2009 Oct; 104(7):934-7.
    View in: PubMed
    Score: 0.063
  63. Association of nonsteroidal anti-inflammatory drugs, prostate specific antigen and prostate volume. J Urol. 2009 May; 181(5):2064-70.
    View in: PubMed
    Score: 0.063
  64. Erectile function outcome reporting after clinically localized prostate cancer treatment. J Urol. 2007 Aug; 178(2):597-601.
    View in: PubMed
    Score: 0.056
  65. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol. 2007 Jun; 177(6):2106-31.
    View in: PubMed
    Score: 0.056
  66. Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study. J Urol. 2007 May; 177(5):1777-81.
    View in: PubMed
    Score: 0.056
  67. Comparison of length of hospital stay between radical retropubic prostatectomy and robotic assisted laparoscopic prostatectomy. J Urol. 2007 Mar; 177(3):929-31.
    View in: PubMed
    Score: 0.055
  68. Prostate volume modifies the association between obesity and prostate cancer or high-grade prostatic intraepithelial neoplasia. Cancer Causes Control. 2007 May; 18(4):375-84.
    View in: PubMed
    Score: 0.055
  69. Urothelial carcinoma of the prostate. Urology. 2007 Jan; 69(1 Suppl):50-61.
    View in: PubMed
    Score: 0.054
  70. Toxicity following high-dose salvage radiotherapy after radical prostatectomy. BJU Int. 2007 Mar; 99(3):529-33.
    View in: PubMed
    Score: 0.054
  71. Significance of atypical and suspicious small acinar proliferations, and high grade prostatic intraepithelial neoplasia on prostate biopsy: implications for cancer detection and biopsy strategy. J Urol. 2006 Mar; 175(3 Pt 1):929-33; discussion 933.
    View in: PubMed
    Score: 0.051
  72. Robotic assisted laparoscopic radical prostatectomy versus retropubic radical prostatectomy: a prospective assessment of postoperative pain. J Urol. 2005 Sep; 174(3):912-4; discussion 914.
    View in: PubMed
    Score: 0.049
  73. Adverse prognostic significance of capsular incision with radical retropubic prostatectomy. J Urol. 2004 Jul; 172(1):119-23.
    View in: PubMed
    Score: 0.046
  74. Incidence and location of prostate and urothelial carcinoma in prostates from cystoprostatectomies: implications for possible apical sparing surgery. J Urol. 2004 Feb; 171(2 Pt 1):646-51.
    View in: PubMed
    Score: 0.044
  75. Randomized prospective evaluation of extended versus limited lymph node dissection in patients with clinically localized prostate cancer. J Urol. 2003 Jan; 169(1):145-7; discussion 147-8.
    View in: PubMed
    Score: 0.041
  76. [Incidence and clinical significance of false-negative sextant biopsies of the prostate]. Urologe A. 1998 Nov; 37(6):660.
    View in: PubMed
    Score: 0.031
  77. Repeat transrectal ultrasound-guided prostate biopsy: a strategy to improve the reliability of needle biopsy grading in patients with well-differentiated prostate cancer. Urology. 1998 Oct; 52(4):659-62.
    View in: PubMed
    Score: 0.031
  78. Incidence and clinical significance of false-negative sextant prostate biopsies. J Urol. 1998 Apr; 159(4):1247-50.
    View in: PubMed
    Score: 0.030
  79. Clinical significance of repeat sextant biopsies in prostate cancer patients. Urology. 1997 Mar; 49(3A Suppl):113-8.
    View in: PubMed
    Score: 0.027
  80. The indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center results. Urology. 1997 Mar; 49(3A Suppl):46-55.
    View in: PubMed
    Score: 0.027
  81. Evaluating neoadjuvant therapy effectiveness on systemic disease: use of a prostatic-specific membrane reverse transcription polymerase chain reaction. Urology. 1997 Mar; 49(3A Suppl):95-101.
    View in: PubMed
    Score: 0.027
  82. Association between prostate-specific antigen and leptin, adiponectin, HbA1c or C-peptide among African-American and Caucasian men. Prostate Cancer Prostatic Dis. 2008; 11(3):264-9.
    View in: PubMed
    Score: 0.014
  83. Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial. Contemp Clin Trials. 2007 Nov; 28(6):763-9.
    View in: PubMed
    Score: 0.014
  84. Androgen and anti-androgen treatment modulates androgen receptor activity and DJ-1 stability. Prostate. 2006 Aug 01; 66(11):1177-93.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.